AUS
NZ
UK
CA
USA
IND
Highlights
- Arecor partners with a global pharmaceutical-focused subsidiary for the exclusive licensing of AT351, a ready-to-dilute (RTD) liquid drug.
- The agreement includes upfront, milestone payments, royalties, and a path to U.S. FDA approval within three years.
- AT351 aims to simplify critical care therapy preparation and improve cost-efficiency across the supply chain.
Arecor Therapeutics plc (LSE:AREC), a biopharmaceutical company dedicated to enhancing therapies for healthier lives, has announced an exclusive licensing agreement for AT351, a ready-to-dilute (RTD) liquid drug product. The agreement is with a wholly owned subsidiary of one of the world’s largest independent chemical marketing companies, which specializes in pharmaceutical development and commercialization.
Innovative Collaboration and Licensing Terms
The licensing agreement follows a successful collaboration in which Arecor utilized its proprietary Arestat™ technology platform to create a differentiated RTD formulation of AT351. This formulation addresses critical care needs by replacing resource-intensive storage and preparation processes, offering a streamlined point-of-use solution.
Under the terms of the deal, Arecor receives an undisclosed upfront payment and is eligible for additional development, regulatory, and commercial milestone payments, along with royalties from global sales. The licensee gains an exclusive, worldwide license to AT351 and its intellectual property, assuming responsibility for all further development, regulatory approvals, and commercialization activities.
The licensee plans to pursue U.S. Food and Drug Administration (FDA) approval for AT351 through the 505(b)(2) regulatory pathway, with submission expected within three years.
Transforming Critical Care Therapy
AT351, an undisclosed but widely used critical care therapy, has the potential to be a first-in-class RTD liquid formulation. By eliminating the lengthy and resource-heavy preparation processes associated with current options, AT351 aims to simplify point-of-use care, reduce costs across the supply chain, and improve patient access.
A Step Forward in Biopharmaceutical Innovation
With the successful licensing of AT351, Arecor strengthens its position as a leader in biopharmaceutical innovation. This milestone underscores the company's ability to form strategic partnerships and leverage its proprietary technology to create impactful healthcare solutions.
